NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization513.41 mln
Float164 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-3.22
Reliable
1-Year Forecast
16.06
Transformational upside
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.13
Very low leverage
ROE
-45.63
Deeply negative
Business Description
Altimmune is a medical research company working to bring new treatments to patients suffering from serious liver conditions. Its main drug in development, pemvidutide, targets two key biological pathways at once and is currently being tested in late-stage clinical trials for liver disease linked to metabolic dysfunction as well as alcohol-related conditions. Founded in 1997 and based in Gaithersburg, Maryland, the company is focused on advancing this treatment toward potential approval.
